Snow David P. 4
4 · Eloxx Pharmaceuticals, Inc. · Filed Jan 31, 2020
Insider Transaction Report
Form 4
Snow David P.
Chief Business Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2020-01-30+6,250→ 18,750 total→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2020-01-30+6,250→ 6,250 total - Tax Payment
Common Stock
2020-01-30$3.91/sh−2,045$7,996→ 4,205 total
Footnotes (4)
- [F1]The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F3]The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
- [F4]The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances.